<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 15 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): September 3, 1998
Commission file number: 1-12529
NETMED, INC.
(Exact name of Registrant as specified in its charter)
OHIO 31-1282391
(State of incorporation (I.R.S. Employer
or organization) Identification No.)
6189 MEMORIAL DRIVE, DUBLIN, OHIO 43017
(Address of principal executive offices, including zip code)
(614) 793-9356
(Registrant's telephone number, including area code)
ITEM 5.
NETMED, INC. Announces Closing of Offering
On September 3, 1998, NetMed, Inc. announced that it had received all
payments and now will close escrow for the previously announced $500,000 private
placement in its 95 percent owned OxyNet subsidiary. Net proceeds to the Company
will be $491,000. The Company also stated that it was not soliciting additional
subscriptions at this time.
"This funding makes two important points," stated David J. Richards, NetMed
president and CEO. "First - The Company projects that there is adequate funding
for operations into the year 2000. Second - educated investors, including our
directors, have invested at a private valuation equivalent to $.62 per NetMed
share only for our oxygen technology. This also is why officers of the Company
have recently purchased NetMed stock in the open market. We believe our stock is
significantly undervalued."
Tuesday September 1, 1998, the Company announced the appointment of Trevor
Ferger as Chief Operating Officer. NetMed, Inc. is engaged in the business of
acquiring, developing and marketing medical and health-related technologies. The
Company's revenues are currently derived from the marketing of the PAPNET(R)
Testing System, an advanced computerized test that pinpoints and magnifies
pre-cancerous cells on conventionally prepared Pap smears. The Company recently
announced that the PAPNET testing system was been approved as a primary
screening device in Canada. The PAPNET testing system is in use as a primary
screening system in several European countries and is currently in FDA trials in
the United States for clearance as a primary screener for all types of Pap
smears. The Company, through its OxyNet subsidiary, is developing a ceramic
oxygen concentrator for use in the home healthcare market.
<PAGE> 2
Statements in this release which relate to other than strictly historical facts,
including statements about the Company's plans and strategies, as well as
management's expectations about new and existing products, technologies and
opportunities, market growth, demand for and acceptance of new and existing
products (including the PAPNET(R) Testing System and the OxyNet(R) oxygen
concentration device), are forward-looking statements. The words "believe,"
"expect," "anticipate," "estimate," "project," and similar expressions identify
forward-looking statements that speak only as of the date hereof. Investors are
cautioned that such statements involve risks and uncertainties that could cause
actual results to differ materially from historical or anticipated results due
to many factors including, but not limited to, the Company's current reliance on
a single product marketed under license from NSI, the corresponding dependence
on NSI's patents and proprietary technology, government regulation, continuing
losses from operations and negative cash flow, limited marketing and sales
history, the impact of third party reimbursement decisions, the challenges of
research and development of new products, and other risks detailed in the
Company's most recent Annual Report on Form 10-K and other Securities and
Exchange Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned herunto duly authorized in Dublin, Ohio on this 9th day of
September, 1998.
By: /s/ David J. Richards
----------------------
David J. Richards, President
